Recombinant anti-Akt Nanobody, Clone # Nb10, COOH-terminal HA tag.
Type: VHH single domain
Source: E. coli
Applications: ELISA, Immunoprecipitation, Pull down
Clonality: Monoclonal
Background: Pan-Akt VHH Antibody was produced in a llama with a recombinant full length Akt then cloned for recombinant production in E. coli cells. Akt kinases are three highly homologous (Akt 1, 2, 3) isoforms of serine/threonine kinases. Akt, also known as protein kinase b (PKB) is frequently over-activated in cancer and considered as a therapeutic target. However, most small molecule inhibitors lack sufficient specificity and to date there are no effective isoform-specific inhibitors available.
Recombinant anti-Akt Nanobody 10 was developed by Gulliver Biomed.
Storage
Store at -20°C upon arrival. For long term storage, aliquot and store at -80°C. Avoid repeated freeze/thaw cycles.
Publications
1) Merckaert, T. et al. (2020). Development and characterization of protein kinase B/AKT isoform-specific nanobodies. PLoS One. 15:e0240554.
2) Merckaert, T. et al. (2021). An AKT2-specific nanobody that targets the hydrophobic motif induces cell cycle arrest, autophagy and loss of focal adhesions in MDA-MB-231 cells.
Biomed Pharmacother. 133:111055.
Keywords: Akt, protein kinase b, PKB, nanobody, VHH, antibody
‘Nanobody’ and ‘nanobodies’ are registered trademarks of Ablynx N.V.
